Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Investig. 2007;117(5):1137–46.
Mandal CC, Mehta J, Prajapati VK. Programmed Dying 1 (PD 1)-mediated T-Cell apoptosis and most cancers immunotherapy. Apoptosis Past Many Methods Cells Die. 2018. https://doi.org/10.1002/9781119432463.ch29.
Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade remedy for most cancers: an outline of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018;62:29–39.
Ordikhani F, et al. Focusing on antigen-presenting cells by anti–PD-1 nanoparticles augments antitumor immunity. JCI perception. 2018. https://doi.org/10.1172/jci.perception.122700.
Xu S, et al. PD-L1 monoclonal antibody-conjugated nanoparticles improve drug supply degree and chemotherapy efficacy in gastric most cancers cells. Int J Nanomed. 2019;14:17.
Guo L, Zhang H, Chen B. Nivolumab as programmed Dying-1 (PD-1) inhibitor for focused immunotherapy in tumor. J Most cancers. 2017;8(3):410–6.
June CH, et al. CAR T cell immunotherapy for human most cancers. Science. 2018;359(6382):1361–5.
Kimiz-Gebologlu I, Gulce-Iz S, Biray-Avci C. Monoclonal antibodies in most cancers immunotherapy. Mol Biol Rep. 2018;45(6):2935–40.
Lee L, Gupta M, Sahasranaman S. Immune Checkpoint inhibitors: An introduction to the next-generation most cancers immunotherapy. J Clin Pharmacol. 2016;56(2):157–69.
Qin S, et al. Novel immune checkpoint targets: shifting past PD-1 and CTLA-4. Mol Most cancers. 2019;18(1):1–14.
Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, variations, and implications of their inhibition. Am J Clin Oncol. 2016;39(1):98.
Vaddepally RK, et al. Overview of indications of FDA-approved immune checkpoint inhibitors per NCCN pointers with the extent of proof. Cancers. 2020. https://doi.org/10.3390/cancers12030738.
Andrews LP, et al. LAG 3 (CD 223) as a most cancers immunotherapy goal. Immunol Rev. 2017;276(1):80–96.
Monney L, et al. Th1-specific cell floor protein Tim-3 regulates macrophage activation and severity of an autoimmune illness. Nature. 2002;415(6871):536–41.
Yu X, et al. The floor protein TIGIT suppresses T cell activation by selling the era of mature immunoregulatory dendritic cells. Nat Immunol. 2009;10(1):48.
Yu X, et al. BTLA/HVEM signaling: milestones in analysis and position in power hepatitis B virus an infection. Entrance Immunol. 2019;10:617.
Wang L, et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med. 2011;208(3):577–92.
Chapoval AI, et al. B7–H3: a costimulatory molecule for T cell activation and IFN-γ manufacturing. Nat Immunol. 2001;2(3):269–74.
Siefker-Radtke A, Curti B. Immunotherapy in metastatic urothelial carcinoma: deal with immune checkpoint inhibition. Nat Rev Urol. 2018;15(2):112.
Minn AJ, Wherry EJ. Mixture most cancers therapies with immune checkpoint blockade: convergence on interferon signaling. Cell. 2016;165(2):272–5.
Fan Q, et al. Towards biomaterials for enhancing immune checkpoint blockade remedy. Adv Func Mater. 2018;28(37):1802540.
Robert C. A decade of immune-checkpoint inhibitors in most cancers remedy. Nat Commun. 2020;11(1):1–3.
Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the therapy of most cancers: medical affect and mechanisms of response and resistance. Annu Rev Pathol. 2021;16(1):223–49.
Baxi S, et al. Immune-related adversarial occasions for anti-PD-1 and anti-PD-L1 medication: systematic evaluation and meta-analysis. BMJ. 2018. https://doi.org/10.1136/bmj.k793.
Khan S, Gerber DE. Autoimmunity, checkpoint inhibitor remedy and immune-related adversarial occasions: a evaluation. Seminars Most cancers Biol. 2020. https://doi.org/10.1016/j.semcancer.2019.06.012.
Okiyama N, Tanaka R. Immune-related adversarial occasions in numerous organs attributable to immune checkpoint inhibitors. Allergol Int. 2022;71(2):169–78.
Michot J, et al. Immune-related adversarial occasions with immune checkpoint blockade: a complete evaluation. Eur J Most cancers. 2016;54:139–48.
Thangavelu G, et al. Programmed death-1 is required for systemic self-tolerance in newly generated T cells throughout the institution of immune homeostasis. J Autoimmun. 2011;36(3–4):301–12.
Rivera IO, et al. PD-L1/PD-1 immunotherapy modulates effector T cells homeostasis and performance in murine pancreatic most cancers. J Immunol. 2016. https://doi.org/10.4049/jimmunol.196.Supp.72.11.
Martins F, et al. Opposed results of immune-checkpoint inhibitors: epidemiology, administration and surveillance. Nat Rev Clin Oncol. 2019;16(9):563–80.
Hussaini S, et al. Affiliation between immune-related negative effects and efficacy and advantage of immune checkpoint inhibitors—a scientific evaluation and meta-analysis. Most cancers Deal with Rev. 2021;92: 102134.
Corsello SM, et al. Endocrine negative effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab. 2013;98(4):1361–75.
Lamichhane P, et al. Novel supply techniques for checkpoint inhibitors. Medicines. 2019;6(3):74.
Francis DM, Thomas SN. Progress and alternatives for enhancing the supply and efficacy of checkpoint inhibitors for most cancers immunotherapy. Adv Drug Deliv Rev. 2017;114:33–42.
Musetti S, Huang L. Nanoparticle-mediated transforming of the tumor microenvironment to boost immunotherapy. ACS Nano. 2018;12(12):11740–55.
Tune W, Musetti SN, Huang L. Nanomaterials for most cancers immunotherapy. Biomaterials. 2017;148:16–30.
Hu X, et al. Nanotechnology primarily based therapeutic modality to spice up anti-tumor immunity and collapse tumor protection. J Management Launch. 2017;256:26–45.
Kelly SH, et al. Biomaterial methods for producing therapeutic immune responses. Adv Drug Deliv Rev. 2017;114:3–18.
Xie YQ, Wei L, Tang L. Immunoengineering with biomaterials for enhanced most cancers immunotherapy. Wiley Interdisciplinary Rev Nanomed Nanobiotechnol. 2018;10(4): e1506.
Ma Q, et al. Artificial poly (L-glutamic acid)-conjugated CpG displays antitumor efficacy with elevated retention in tumor and draining lymph nodes after intratumoral injection in a mouse mannequin of melanoma. J Immunother. 2017;40(1):11.
Ott PA, et al. Mixture immunotherapy: a highway map. J Immunother Most cancers. 2017;5(1):1–15.
Lahori DG, Varamini P. Nanotechnology-based platforms to enhance immune checkpoint blockade efficacy in most cancers remedy. Future Oncol. 2021;17(6):711–22.
Yu Z, et al. Mixed utility of nanotechnology and a number of therapies with tumor immune checkpoints. ChemistrySelect. 2020;5(47):14943–54.
Koshy ST, Mooney DJ. Biomaterials for enhancing anti-cancer immunity. Curr Opin Biotechnol. 2016;40:1–8.
Principe N, et al. Complete testing of chemotherapy and immune checkpoint blockade in preclinical most cancers fashions identifies additive combos. Entrance Immunol. 2022;13: 872295.
Walsh RJ, Sundar R, Lim JSJ. Immune checkpoint inhibitor combinations-current and rising methods. Br J Most cancers. 2023;128(8):1415–7.
Liu Q, et al. Nano-immunotherapy: distinctive mechanisms of nanomaterials in synergizing most cancers immunotherapy. Nano At this time. 2021;36: 101023.
Guevara ML, Persano F, Persano S. Nano-immunotherapy: overcoming tumour immune evasion. Seminars Most cancers Biol. 2019. https://doi.org/10.1016/j.semcancer.2019.11.010.
Larkins E, et al. FDA approval abstract: pembrolizumab for the therapy of recurrent or metastatic head and neck squamous cell carcinoma with illness development on or after platinum-containing chemotherapy. Oncologist. 2017;22(7):873.
Paik J. Nivolumab plus relatlimab: first approval. Medication. 2022;82(8):925–31.
Wu Y, et al. Silencing PD-1 and PD-L1 with nanoparticle-delivered small interfering RNA will increase cytotoxicity of tumor-infiltrating lymphocytes. Nanomedicine. 2019;14(8):955–67.
Barshidi A, et al. Twin Blockade of PD-1 and LAG3 immune checkpoints will increase dendritic cell vaccine mediated T cell responses in breast most cancers mannequin. Pharm Res. 2022;39(8):1851–66.
Tune W, et al. Synergistic and low adversarial impact most cancers immunotherapy by immunogenic chemotherapy and domestically expressed PD-L1 lure. Nat Commun. 2018;9(1):1–11.
Tran A, Fierro J, Dou H. CSIG-11 concentrating on PD-L1 IN glioblastoma utilizing nanoparticle-based gene modifying. Neuro-Oncol. 2020. https://doi.org/10.1093/neuonc/noaa215.123.
Offringa R, et al. The increasing position for small molecules in immuno-oncology. Nat Rev Drug Discovery. 2022;21(11):821–40.
Wu Q, et al. Small-molecule inhibitors, immune checkpoint inhibitors, and extra: FDA-approved novel therapeutic medication for stable tumors from 1991 to 2021. J Hematol Oncol. 2022. https://doi.org/10.1186/s13045-022-01362-9.
Sasikumar PG, Ramachandra M. Small-Molecule immune checkpoint inhibitors concentrating on PD-1/PD-L1 and different rising checkpoint pathways. BioDrugs. 2018;32(5):481–97.
Sasikumar PG, et al. PD-1 derived CA-170 is an oral immune checkpoint inhibitor that displays preclinical anti-tumor efficacy. Commun Biol. 2021;4(1):1–12.
Radhakrishnan V, et al. Glorious CBR and extended PFS in non-squamous NSCLC with oral CA-170, an inhibitor of VISTA and PD-L1. Ann Oncol. 2019;30: v494.
Ragelle H, et al. Chitosan nanoparticles for SiRNA supply in vitro. Strategies Mol Biol. 2016;1364:143–50.
Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable managed drug supply provider. Polymers. 2011;3(3):1377–97.
Surendran SP, et al. Bioactive nanoparticles for most cancers immunotherapy. Int J Mol Sci. 2018. https://doi.org/10.3390/ijms19123877.
Schmid D, et al. T cell-targeting nanoparticles focus supply of immunotherapy to enhance antitumor immunity. Nat Commun. 2017;8(1):1747.
Paz-Ares L, et al. First-line nivolumab plus ipilimumab mixed with two cycles of chemotherapy in sufferers with non-small-cell lung most cancers (CheckMate 9LA): a world, randomised, open-label, part 3 trial. Lancet Oncol. 2021;22(2):198–211.
Luo L, et al. Laser immunotherapy together with perdurable PD-1 blocking for the therapy of metastatic tumors. ACS Nano. 2018;12(8):7647–62.
Ghasemi-Chaleshtari M, et al. Concomitant blockade of A2AR and CTLA-4 by siRNA-loaded polyethylene glycol-chitosan-alginate nanoparticles synergistically enhances antitumor T-cell responses. J Cell Physiol. 2020;235(12):10068–80.
Hess KL, Medintz IL, Jewell CM. Designing inorganic nanomaterials for vaccines and immunotherapies. Nano At this time. 2019;27:73–98.
Ngobili TA, Daniele MA. Nanoparticles and direct immunosuppression. Exp Biol Med. 2016;241(10):1064–73.
Khelghati N, et al. The significance of co-delivery of nanoparticle-siRNA and anticancer brokers in most cancers remedy. Chem Biol Drug Des. 2021;97(4):997–1015.
Pecot CV, et al. RNA interference within the clinic: challenges and future instructions. Nat Rev Most cancers. 2011;11(1):59–67.
Chen Y, et al. Blood clot scaffold loaded with liposome vaccine and siRNAs Focusing on PD-L1 and TIM-3 for efficient DC activation and most cancers immunotherapy. ACS Nano. 2023;17(1):760–74.
Strop P, et al. Location issues: website of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem Biol. 2013;20(2):161–7.
Mitchell MJ, et al. Engineering precision nanoparticles for drug supply. Nat Rev Drug Discov. 2021;20(2):101–24.
Lee H, et al. (64)Cu-MM-302 positron emission tomography quantifies variability of enhanced permeability and retention of nanoparticles in relation to therapy response in sufferers with metastatic breast most cancers. Clin Most cancers Res. 2017;23(15):4190–202.
Li HJ, et al. Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy. Proc Natl Acad Sci USA. 2016;113(15):4164–9.
Rodallec A, et al. Turning chilly tumors into sizzling tumors: harnessing the potential of tumor immunity utilizing nanoparticles. Skilled Opin Drug Metab Toxicol. 2018;14(11):1139–47.
Chen G, et al. Nanochemistry and nanomedicine for nanoparticle-based diagnostics and remedy. Chem Rev. 2016;116(5):2826–85.
Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an rising therapy modality for most cancers. Nat Rev Drug Discov. 2008;7(9):771–82.
Toy R, Roy Okay. Engineering nanoparticles to beat limitations to immunotherapy. Bioeng Transl Med. 2016;1(1):47–62.
Huang Y, Zeng J. Latest improvement and purposes of nanomaterials for most cancers immunotherapy. Nanotechnol Rev. 2020;9(1):367–84.
Shen S, et al. Immunosuppressive nanoparticles for administration of immune-related adversarial occasions in liver. ACS Nano. 2021;15(5):9111–25.
Xiong Y, Wang Y, Tiruthani Okay. Tumor immune microenvironment and nano-immunotherapeutics in colorectal most cancers. Nanomed Nanotechnol Biol Med. 2019;21:102034.
Jurj A, et al. The brand new period of nanotechnology, a substitute for change most cancers therapy. Drug Des Devel Ther. 2017;11:2871–90.
Gu Z, et al. Liposome-based drug supply techniques in most cancers immunotherapy. Pharmaceutics. 2020;12(11):1054.
Lee ES, et al. Latest advances in polymeric nanomedicines for most cancers immunotherapy. Adv Healthcare Mater. 2019;8(4):1801320.
Zeng Q, et al. Tailoring polymeric hybrid micelles with lymph node concentrating on capacity to enhance the efficiency of most cancers vaccines. Biomaterials. 2017;122:105–13.
Kiaie SH, et al. Axial pharmaceutical properties of liposome in most cancers remedy: latest advances and views. Int J Pharm. 2020;581: 119269.
Ragelle H, et al. Chitosan nanoparticles for SiRNA supply in vitro, in SiRNA Supply Strategies. Berlinp: Springer; 2016.
Zakeri A, et al. Polyethylenimine-based nanocarriers in co-delivery of drug and gene: a growing horizon. Nano Rev Exp. 2018;9(1):1488497.
Esmaily M, et al. Blockade of CTLA-4 will increase anti-tumor response inducing potential of dendritic cell vaccine. J Management Rel. 2020;326:63–74.
Jiao Q, et al. Immunomodulation of nanoparticles in nanomedicine purposes. BioMed Res Int. 2014. https://doi.org/10.1155/2014/426028.
Ou W, et al. Regulatory T cell-targeted hybrid nanoparticles mixed with immuno-checkpoint blockage for most cancers immunotherapy. J Management Launch. 2018;281:84–96.
He C, Lu J, Lin W. Hybrid nanoparticles for mixture remedy of most cancers. J Management Launch. 2015;219:224–36.
Wan WJ, et al. Doxorubicin and siRNA-PD-L1 co-delivery with T7 modified ROS-sensitive nanoparticles for tumor chemoimmunotherapy. Int J Pharm. 2019;566:731–44.
Wang Y, et al. IR792-MCN@ZIF-8-PD-L1 siRNA drug supply system enhances photothermal immunotherapy for triple-negative breast most cancers below near-infrared laser irradiation. J Nanobiotechnol. 2022;20(1):96.
Hu Q, et al. Combinational chemoimmunotherapy for breast most cancers by codelivery of doxorubicin and PD-L1 siRNA Utilizing a PAMAM-incorporated liposomal nanoplatform. ACS Appl Mater Interfaces. 2022;14(7):8782–92.
Camorani S, et al. Aptamer-functionalized nanoparticles mediate PD-L1 siRNA supply for efficient gene silencing in triple-negative breast most cancers cells. Pharmaceutics. 2022. https://doi.org/10.3390/pharmaceutics14102225.
Gong T, et al. A nanodrug incorporating siRNA PD-L1 and Birinapant for enhancing tumor immunotherapy. Biomaterials Sci. 2021;9(23):8007–18.
Pacheco-Torres J, et al. PD-L1 siRNA theranostics with a dextran nanoparticle highlights the significance of nanoparticle supply for efficient tumor PD-L1 Downregulation. Entrance Oncol. 2021. https://doi.org/10.3389/fonc.2020.614365.
Chen M, Chen M, He J. Most cancers cell membrane cloaking nanoparticles for focused co-delivery of doxorubicin and PD-L1 siRNA. Synthetic Cells Nanomed Biotechnol. 2019;47(1):1635–41.
Li C, Han X. Melanoma most cancers immunotherapy utilizing PD-L1 siRNA and imatinib promotes cancer-immunity cycle. Pharm Res. 2020;37(6):109.
Wang D, et al. Acid-activatable versatile micelleplexes for PD-L1 blockade-enhanced most cancers photodynamic immunotherapy. Nano Lett. 2016;16(9):5503–13.
Dai L, et al. Measurement/cost changeable acidity-responsive micelleplex for photodynamic-improved PD-L1 immunotherapy with enhanced tumor penetration. Adv Func Mater. 2018;28(18):1707249.
Bastaki S, et al. Codelivery of STAT3 and PD-L1 siRNA by hyaluronate-TAT trimethyl/thiolated chitosan nanoparticles suppresses most cancers development in tumor-bearing mice. Life Sci. 2021;266: 118847.
Li X, et al. Liposomal Co-delivery of PD-L1 siRNA/Anemoside B4 for enhanced combinational immunotherapeutic impact. ACS Appl Mater Interfaces. 2022;14(25):28439–54.
Gao L, et al. Development of PD-L1-siRNA and IL-2 DNA loading PEI lipid nanoparticles in activating T cells and treating lung most cancers. AIP Adv. 2021;11(4): 045201.
Luo X, et al. Folic acid-functionalized polyethylenimine superparamagnetic iron oxide nanoparticles as theranostic brokers for magnetic resonance imaging and PD-L1 siRNA supply for gastric most cancers. Int J Nanomed. 2017;12:5331.
Huang Okay-W, et al. Extremely environment friendly and tumor-selective nanoparticles for dual-targeted immunogene remedy in opposition to most cancers. Sci Adv. 2020. https://doi.org/10.1126/sciadv.aax5032.
Yoo B, et al. RNAi-Mediated PD-L1 inhibition for pancreatic most cancers immunotherapy. Sci Rep. 2019;9(1):4712.
Ruan H, et al. A dual-bioresponsive drug-delivery depot for mixture of epigenetic modulation and immune checkpoint blockade. Adv Mater. 2019;31(17):1806957.
Wang C, et al. Enhanced most cancers immunotherapy by microneedle patch-assisted supply of anti-PD1 antibody. Nano Lett. 2016;16(4):2334–40.
Wang C, et al. Irritation-triggered most cancers immunotherapy by programmed supply of CpG and anti-PD1 antibody. Adv Mater. 2016;28(40):8912–20.
Su Z, et al. Codelivery of Anti-PD-1 antibody and paclitaxel with matrix metalloproteinase and pH dual-sensitive micelles for enhanced tumor chemoimmunotherapy. Small. 2020;16(7): e1906832.
Mi Y, et al. A twin immunotherapy nanoparticle improves T-cell activation and most cancers immunotherapy. Adv Mater. 2018;30(25):1706098.
Li Y, et al. A dendritic cell-like biomimetic nanoparticle enhances T cell activation for breast most cancers immunotherapy. Chem Sci. 2022;13(1):105–10.
Kosmides AK, et al. Twin concentrating on nanoparticle stimulates the immune system to inhibit tumor development. ACS Nano. 2017;11(6):5417–29.
Reda M, et al. Improvement of a nanoparticle-based immunotherapy concentrating on PD-L1 and PLK1 for lung most cancers therapy. Nat Commun. 2022;13(1):4261.
Zhang P, et al. Therapeutic concentrating on of tumor-associated myeloid cells synergizes with radiation remedy for glioblastoma. Proc Natl Acad Sci. 2019;116(47):23714–23.
Goodwin TJ, et al. Liver particular gene immunotherapies resolve immune suppressive ectopic lymphoid constructions of liver metastases and lengthen survival. Biomaterials. 2017;141:260–71.
Miao L, et al. Transient and native expression of chemokine and immune checkpoint traps to deal with pancreatic most cancers. ACS Nano. 2017;11(9):8690–706.
Gautam A, et al. Plant viral nanoparticle conjugated with anti-PD-1 peptide for ovarian most cancers immunotherapy. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms22189733.
Luo L, et al. Sustained launch of anti-PD-1 peptide for perdurable immunotherapy along with photothermal ablation in opposition to main and distant tumors. J Management Launch. 2018;278:87–99.
Wu L, et al. Intravenous Supply of RNA Encoding Anti-PD-1 Human Monoclonal Antibody for Treating Intestinal Most cancers. J Most cancers. 2022;13(2):579–88.
Li SY, et al. Restoring anti-tumor features of T cells by way of nanoparticle-mediated immune checkpoint modulation. J Management Rel. 2016;231:17–28.
Lei C, et al. Native launch of extremely loaded antibodies from functionalized nanoporous assist for most cancers immunotherapy. J Am Chem Soc. 2010;132(20):6906–7.
Rahimian S, et al. Polymeric microparticles for sustained and native supply of antiCD40 and antiCTLA-4 in immunotherapy of most cancers. Biomaterials. 2015;61:33–40.
Solar J-J, et al. Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin by way of a redox-responsive immunostimulatory polymeric prodrug provider. Acta Pharmacol Sin. 2017;38(6):823–34.
Tune C, et al. Improved anti-hepatocellular carcinoma impact by enhanced Co-delivery of Tim-3 siRNA and sorafenib by way of a number of pH triggered drug-eluting nanoparticles. Supplies At this time Bio. 2022;16: 100350.
Chen C, et al. Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast most cancers development and metastasis. Biomaterials. 2021;275: 120988.
Zhang X, et al. PD-1 blockade mobile vesicles for most cancers immunotherapy. Adv Mater. 2018;30(22):1707112.
Ye Y, et al. Synergistic transcutaneous immunotherapy enhances antitumor immune responses by means of supply of checkpoint inhibitors. ACS Nano. 2016;10(9):8956–63.
Galstyan A, et al. Blood–mind barrier permeable nano immunoconjugates induce native immune responses for glioma remedy. Nat Commun. 2019;10(1):1–13.
Kwak SY, et al. PLGA Nanoparticles codelivering siRNAs in opposition to programmed cell loss of life protein-1 and its ligand gene for suppression of colon tumor development. Mol Pharm. 2019;16(12):4940–53.
Shariati M, et al. Aerosolization of nanotherapeutics as a newly rising therapy routine for peritoneal carcinomatosis. Cancers. 2019. https://doi.org/10.3390/cancers11070906.
Huang X, et al. Provider-free multifunctional nanomedicine for intraperitoneal disseminated ovarian most cancers remedy. J Nanobiotechnology. 2022;20(1):93.
Ornella MSC, et al. Immunotherapy for peritoneal carcinomatosis: challenges and potential outcomes. Cancers. 2023. https://doi.org/10.3390/cancers15082383.
Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and sign transduction. Immunol Rev. 2009;229(1):12–26.
Pardoll DM. The blockade of immune checkpoints in most cancers immunotherapy. Nat Rev Most cancers. 2012;12(4):252–64.
Alsaab HO, et al. PD-1 and PD-L1 checkpoint signaling inhibition for most cancers immunotherapy: mechanism, combos, and medical end result. Entrance Pharmacol. 2017;8:561.
Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227–42.
Ramsay AG. Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity. Br J Haematol. 2013;162(3):313–25.
Butt A, Mills Okay. Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade within the improvement of most cancers immunotherapeutics and vaccines. Oncogene. 2014;33(38):4623–31.
Webster RM. The immune checkpoint inhibitors: the place are we now? Nature opinions. Drug discovery. 2014;13(12):883.
Ghassemi AH, et al. Managed launch of octreotide and evaluation of peptide acylation from poly (D, L-lactide-co-hydroxymethyl glycolide) in comparison with PLGA microspheres. Pharm Res. 2012;29(1):110–20.
Lim M, et al. Present state of immunotherapy for glioblastoma. Nat Rev Clin Oncol. 2018;15(7):422–42.
Wainwright DA, et al. Sturdy therapeutic efficacy using combinatorial blockade in opposition to IDO, CTLA-4, and PD-L1 in mice with mind tumors. Clin Most cancers Res. 2014;20(20):5290–301.
Belcaid Z, et al. Focal radiation remedy mixed with 4–1BB activation and CTLA-4 blockade yields long-term survival and a protecting antigen-specific reminiscence response in a murine glioma mannequin. PLoS ONE. 2014;9(7): e101764.
Villaseñor R, et al. Trafficking of endogenous immunoglobulins by endothelial cells on the blood-brain barrier. Sci Rep. 2016;6:25658.
Reardon DA, et al. Glioblastoma eradication following immune checkpoint blockade in an orthotopic. Immunocompetent Mannequin Most cancers Immunol Res. 2016;4(2):124–35.
Brennan CW, et al. The somatic genomic panorama of glioblastoma. Cell. 2014;157(3):753.
Fransen MF, et al. Managed native supply of CTLA-4 blocking antibody induces CD8+ T-cell–dependent tumor eradication and reduces threat of poisonous negative effects. Clin Most cancers Res. 2013;19(19):5381–9.
Lei C, et al. Characterization of functionalized nanoporous helps for protein confinement. Nanotechnology. 2006;17(22):5531.
Lei C, et al. Entrapping enzyme in a functionalized nanoporous assist. J Am Chem Soc. 2002;124(38):11242–3.
Xu J, et al. Close to-infrared-triggered photodynamic remedy with multitasking upconversion nanoparticles together with checkpoint blockade for immunotherapy of colorectal most cancers. ACS Nano. 2017;11(5):4463–74.
Curran MA, et al. PD-1 and CTLA-4 mixture blockade expands infiltrating T cells and reduces regulatory T and myeloid cells inside B16 melanoma tumors. Proc Natl Acad Sci. 2010;107(9):4275–80.
Tian M, et al. The PD-1/PD-L1 inhibitory pathway is altered in pre-eclampsia and regulates T cell responses in pre-eclamptic rats. Sci Rep. 2016;6(1):1–14.
Ohaegbulam KC, et al. Human most cancers immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Traits Mol Med. 2015;21(1):24–33.
Muenst S, et al. Expression of programmed loss of life ligand 1 (PD-L1) is related to poor prognosis in human breast most cancers. Breast Most cancers Res Deal with. 2014;146(1):15–24.
Schalper KA. PD-L1 expression and tumor-infiltrating lymphocytes: revisiting the antitumor immune response potential in breast most cancers. Oncoimmunology. 2014;3(6): e29288.
Tang J, et al. Preparation of optimized lipid-coated calcium phosphate nanoparticles for enhanced in vitro gene supply to breast most cancers cells. J Mater Chem B. 2015;3(33):6805–12.
Ma D. Enhancing endosomal escape for nanoparticle mediated siRNA supply. Nanoscale. 2014;6(12):6415–25.
!!! INVALID CITATION !!! {Ma, 2014 #344;Khalilzadeh, 2022 #70}.
Wu Y, et al. Enhancing PD-1 gene silence in T lymphocytes by evaluating the supply efficiency of two inorganic nanoparticle platforms. Nanomaterials. 2019;9(2):159.
Wang C, et al. In situ activation of platelets with checkpoint inhibitors for post-surgical most cancers immunotherapy. Nature Biomedical Engineering. 2017;1(2):1–10.
Marabelle A, et al. Depleting tumor-specific Tregs at a single website eradicates disseminated tumors. J Clin Investig. 2013;123(6):2447–63.
Krieg AM. Toll-like receptor 9 (TLR9) agonists within the therapy of most cancers. Oncogene. 2008;27(2):161–7.
Guo F, et al. CXCL12/CXCR4: a symbiotic bridge linking most cancers cells and their stromal neighbors in oncogenic communication networks. Oncogene. 2016;35(7):816–26.
Kiaie SH, et al. Immune checkpoints in targeted-immunotherapy of pancreatic most cancers: new hope for medical improvement. Acta Pharm Sin B. 2021;11(5):1083–97.
Chiang C-S, et al. Mixture of fucoidan-based magnetic nanoparticles and immunomodulators enhances tumour-localized immunotherapy. Nat Nanotechnol. 2018;13(8):746–54.
Chen X-J, et al. Anti-PD-L1-modified and ATRA-loaded nanoparticles for immuno-treatment of oral dysplasia and oral squamous cell carcinoma. Nanomedicine. 2020;15(10):951–68.
Yu J, et al. Myeloid-derived suppressor cells suppress antitumor immune responses by means of IDO expression and correlate with lymph node metastasis in sufferers with breast most cancers. J Immunol. 2013;190(7):3783–97.
Cheong JE, Solar L. Focusing on the IDO1/TDO2–KYN–AhR pathway for most cancers immunotherapy–challenges and alternatives. Traits Pharmacol Sci. 2018;39(3):307–25.
Xu X, Lu H, Lee R. Close to infrared mild triggered picture/immuno-therapy towards cancers. Entrance Bioeng Biotechnol. 2020;8:488.
Meng X, et al. Photothermal/photodynamic remedy with immune-adjuvant liposomal complexes for efficient gastric most cancers remedy. Half Half Methods Charact. 2019. https://doi.org/10.1002/ppsc.201900015.
Craik DJ, et al. The way forward for peptide-based medication. Chem Biol Drug Des. 2013;81(1):136–47.
Liang C, et al. Rising nanomedicine approaches preventing tumor metastasis: animal fashions, metastasis-targeted drug supply, phototherapy, and immunotherapy. Chem Soc Rev. 2016;45(22):6250–69.